ethyl 2-(4-mercaptophenyl)propionate | 88975-47-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯硫酚类
• 英文名称: ethyl 2-(4-mercaptophenyl)propionate
• 英文别名: ethyl 2-(4-mercaptophenyl)propanoate；ethyl 2-(4-sulfanylphenyl)propanoate
• CAS: 88975-47-7
• 化学式: C₁₁H₁₄O₂S
• 分子量: 210.297
• InChiKey: CRRBZWKPIGEMHJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  14
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  27.3
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  ethyl 2-(4-mercaptophenyl)propionate 在 磺酰氯 、 硫化氢 、 三乙胺 作用下， 以 四氯化碳 、 乙醚 、 乙腈 为溶剂， 反应 2.5h， 生成 ethyl 2-(4-carbamothioylsulfanylphenyl)propanoate
  参考文献：
  名称：

  Studies on the synthesis and analgesic and anti-inflammatory activities of 2-thiazolylamino- and 2-thiazolyloxy-arylacetic acid derivatives.

  摘要：

  根据Hantzsch方法，通过硫酰胺与卤代乙缩醛的缩合反应制备了一系列2-噻唑基氨基、2-噻唑基氧和2-噻唑基硫代芳基乙酸衍生物，而具有α-甲基芳基乙酸部分的硫酰胺则通过结合已知方法从卤代芳香硝基化合物中方便地获得。在O-苯基硫代氨基甲酸酯（XVIII）与氯代二乙缩醛的模型反应中，分离出无环卤代化合物（XIX）和4-乙氧基-2-苯氧基-2-噻唑啉（XX）等中间体，阐明了苯氧噻唑（XXI）的生成反应途径。通过小鼠的醋酸引起的扭体法和大鼠的角叉菜胶引起的足跖肿胀法，分别评估了所研究化合物的镇痛和抗炎作用。2-[4-（2-噻唑氧基）苯基]丙酸（XIVa）在活性与毒性之间具有最佳的治疗比（在小鼠中）。

  DOI：

  10.1248/cpb.31.3424
• 作为产物：
  描述：

  2-苯基丙酸乙酯 在 盐酸 、 氯磺酸 、 tin 作用下， 以 1,4-二氧六环 、 乙醇 、 二氯甲烷 为溶剂， 反应 6.0h， 生成 ethyl 2-(4-mercaptophenyl)propionate
  参考文献：
  名称：

  [EN] ROR GAMMA (RORY) MODULATORS
  [FR] MODULATEURS DU ROR GAMMA (RORY)

  摘要：

  本发明涉及符合以下式I的化合物：其中：A11 - A14分别为N或CR11，CR12，CR13，CR14，但四个位置A中不超过两个可以同时为N；R1为C(1-6)烷基，C(3-6)环烷基，C(3-6)环烷基C(1-3)烷基，(双)C(1-6)烷基氨基，(双)C(3-6)环烷基氨基或(双)(C(3-6)环烷基C(1-3)烷基)氨基，烷基族的所有碳原子可选择性地被一个或多个F取代，环烷基族的所有碳原子可选择性地被一个或多个F或甲基取代；R2和R3独立地为H，F，甲基，乙基，羟基，甲氧基或R2和R3一起为羰基，所有烷基族（如果存在）可选择性地被一个或多个F取代；R4为H或C(1-6)烷基；R5为H，羟乙基，甲氧乙基，C(1-6)烷基，C(6-10)芳基，C(6-10)芳基C(1-3)烷基，C(1-9)杂环芳基，C(1-9)杂环芳基C(1-3)烷基，C(3-6)环烷基，C(3-6)环烷基C(1-3)烷基，C(2-5)杂环烷基或C(2-5)杂环烷基C(1-3)烷基，所有基团可选择性地被一个或多个F，CI，C(1-2)烷基，C(1-2)烷氧基或氰取代；与R1相连的磺酰基由R7，R8或R9之一表示；其余的R6-RH独立地为H，卤素，C(1-3)烷氧基，(双)C(1-3)烷基氨基或C(1-6)烷基，所有烷基族可选择性地被一个或多个F取代；Ri5和Ri6独立地为H，C(1-6)烷基，C(3-6)环烷基，C(3-6)环烷基C(1-3)烷基，C(6-10)芳基，C(6-10)芳基C(1-3)烷基，C(1-9)杂环芳基，C(1-9)杂环芳基C(1-3)烷基，C(2-5)杂环烷基或C(2-5)杂环烷基C(1-3)烷基，所有基团可选择性地被一个或多个F，CI，C(1-2)烷基，C(1-2)烷氧基或氰取代。这些化合物可用作RORγ的抑制剂，并且对于治疗RORγ介导的疾病是有用的。

  公开号：

  WO2015082533A1

文献信息

• Thiazole derivatives of benzoic and phenylalkanoic acids
  申请人：Shionogi & Co., Ltd.

  公开号：US04025528A1

  公开（公告）日：1977-05-24

  Thiazole derivatives represented by the general formula: ##STR1## wherein A is oxygen, sulfur, imino, or NR.sub.3, wherein R.sub.3 is C.sub.1.sub.-5 alkyl, C.sub.2.sub.-5 alkenyl, C.sub.3.sub.-5 alkynyl, C.sub.3.sub.-6 cycloalkyl-C.sub.1.sub.-3 alkyl or C.sub.7.sub.-8 aralkyl; R.sub.1 is hydrogen, C.sub.1.sub.-5 alkyl, C.sub.2.sub.-5 alkenyl, C.sub.3.sub.-5 alkynyl, C.sub.3.sub.-6 cycloalkyl-C.sub.1.sub.-3 alkyl or C.sub.7.sub.- 8 aralkyl; R.sub.2 is hydroxy, C.sub.1.sub.-5 alkoxy or OM, wherein M is alkali metal, or one equivalent of alkaline earth metal, cupric or aluminum cation; n is an integer of 0 or 1; X.sub.1 and X.sub.2 are independently hydrogen or C.sub.1.sub.-5 alkyl; Y.sub.1 and Y.sub.2 are independently hydrogen, halogen, C.sub.1.sub.-5 alkyl, C.sub.1.sub.-5 alkoxy or trifluoromethyl; and the group ##STR2## is linked to one of the meta or para positions of the benzene ring A, n is not 0 when A is imino and --CH.sub.2 --COR.sub.2 does not substitute the thiazole ring when A is imino, being useful as anti-inflammatory, anti-rheumatic, analgesic or anti-lipemia agents.

  通式表示的噻唑衍生物：##STR1## 其中A是氧、硫、亚胺或NR.sub.3，其中R.sub.3是C.sub.1.sub.-5烷基、C.sub.2.sub.-5烯基、C.sub.3.sub.-5炔基、C.sub.3.sub.-6环烷基-C.sub.1.sub.-3烷基或C.sub.7.sub.-8芳基烷基；R.sub.1是氢、C.sub.1.sub.-5烷基、C.sub.2.sub.-5烯基、C.sub.3.sub.-5炔基、C.sub.3.sub.-6环烷基-C.sub.1.sub.-3烷基或C.sub.7.sub.-8芳基烷基；R.sub.2是羟基、C.sub.1.sub.-5烷氧基或OM，其中M是碱金属或一当量的碱土金属、铜离子或铝离子；n是0或1的整数；X.sub.1和X.sub.2独立地是氢或C.sub.1.sub.-5烷基；Y.sub.1和Y.sub.2独立地是氢、卤素、C.sub.1.sub.-5烷基、C.sub.1.sub.-5烷氧基或三氟甲基；以及##STR2## 这个基团连接到苯环A的meta或para位置之一，当A是亚胺时，n不是0，当A是亚胺时，--CH.sub.2 --COR.sub.2不替换噻唑环，这些化合物可用作抗炎、抗风湿、止痛或抗脂质血症剂。
• Thiazole derivatives
  申请人：Shionogi & Co., Ltd.

  公开号：US04077968A1

  公开（公告）日：1978-03-07

  Thiazole derivatives represented by the general formula: ##STR1## wherein A is oxygen, sulfur, imino, or NR.sub.3, wherein R.sub.3 is C.sub.1-5 alkyl, C.sub.2-5 alkenyl, C.sub.3-5 alkynyl, C.sub.3-6 cycloalkyl-C.sub.1-3 alkyl or C.sub.7-8 aralkyl; R.sub.1 is hydrogen, C.sub.1-5 alkyl, C.sub.2-5 alkenyl, C.sub.3-5 alkynyl, C.sub.3-6 cycloalkyl-C.sub.1-3 alkyl or C.sub.7-8 aralkyl; R.sub.2 is hydroxy, C.sub.1-5 alkoxy or OM, wherein M is alkali metal, or one equivalent of alkaline earth metal, cupric or aluminum cation; n is an integer of 0 or 1; X.sub.1 and X.sub.2 are independently hydrogen or C.sub.1-5 alkyl; Y.sub.1 and Y.sub.2 are independently hydrogen, halogen, C.sub.1-5 alkyl, C.sub.1-5 alkoxy or trifluoromethyl; and the group ##STR2## is linked to one of the meta or para positions of the benzene ring A, n is not 0 when A is imino and --CH.sub.2 --COR.sub.2 does not substitute the thiazole ring when A is imino, being useful as anti-inflammatory, anti-rheumatic, analgesic or anti-lipemia agents.

  通式表示的噻唑衍生物：##STR1## 其中A为氧、硫、亚胺或NR.sub.3，其中R.sub.3为C.sub.1-5烷基、C.sub.2-5烯基、C.sub.3-5炔基、C.sub.3-6环烷基-C.sub.1-3烷基或C.sub.7-8芳基烷基；R.sub.1为氢、C.sub.1-5烷基、C.sub.2-5烯基、C.sub.3-5炔基、C.sub.3-6环烷基-C.sub.1-3烷基或C.sub.7-8芳基烷基；R.sub.2为羟基、C.sub.1-5烷氧基或OM，其中M为碱金属或一当量的碱土金属、铜或铝阳离子；n为0或1的整数；X.sub.1和X.sub.2独立地为氢或C.sub.1-5烷基；Y.sub.1和Y.sub.2独立地为氢、卤素、C.sub.1-5烷基、C.sub.1-5烷氧基或三氟甲基；和 ##STR2## 链接到苯环A的其中一个间位或对位，当A为亚胺时，n不为0，且当A为亚胺时，--CH.sub.2--COR.sub.2不取代噻唑环，用作抗炎、抗风湿、镇痛或抗脂质血症剂。
• ROR GAMMA (RORY) MODULATORS
  申请人：Lead Pharma Cel Models IP B.V.

  公开号：EP3077372A1

  公开（公告）日：2016-10-12
• ROR GAMMA (RORy) MODULATORS
  申请人：LEAD PHARMA CEL MODELS IP B.V.

  公开号：US20160304448A1

  公开（公告）日：2016-10-20

  A 11-14 are N or CR 11-14 , respectively, maximum two of the four positions A simultaneously N; R 1 is C(1-6)alkyl, C(3-6)cycloalkyl, C(3-6)cycloalkylC(1-3)alkyl, (di)C(1-6)alkylamino, (di)C(3-6)cycloalkylamino or (di)(C(3-6)cycloalkylC(1-3)alkyl)amino, all alkyl and cycloalkyl group carbon atoms optionally substituted with F and F or methyl, respectively; R 2 and R 3 independently H, F, methyl, ethyl, hydroxy, methoxy or R 2 and R 3 together is carbonyl, all present alkyl groups optionally substituted with F; R 4 is H or C(1-6)alkyl; R 5 is H, hydroxyethyl, methoxyethyl, C(1-6)alkyl, C(6-10)aryl, C(6-10)arylC(1-3)alkyl, C(1-9)heteroaryl, C(1-9)heteroarylC(1-3)alkyl, C(3-6)cycloalkyl, C(3-6)cycloalkylC(1-3)alkyl, C(2-5)heterocycloalkyl or C(2-5)heterocycloalkylC(1-3)alkyl, all groups optionally substituted with F, Cl, C(1-2)alkyl, C(1-2)alkoxy or cyano; the sulfonyl group with R 1 represented by one of R 7-9 ; the remaining R 6-14 are independently H, halogen, C(1-3)alkoxy, (di)C(1-3)alkylamino or C(1-6)alkyl, all alkyl groups optionally substituted with F; and R 15-16 are independently H, C(1-6)alkyl, C(3-6)cycloalkyl, C(3-6)cycloalkylC(1-3)alkyl, C(6-10)aryl, C(6-10)arylC(1-3)alkyl, C(1-9)heteroaryl, C(1-9)heteroarylC(1-3)alkyl, C(2-5)heterocycloalkyl or C(2-5)heterocycloalkylC(1-3)alkyl, all groups optionally substituted with F, Cl, C(1-2)alkyl, C(1-2)alkoxy or cyano.
• US4025528A
  申请人：——

  公开号：US4025528A

  公开（公告）日：1977-05-24